Clinical Trial Update: Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Mirabegron (Myrbetriq) to reduce pain and discomfort after ureteral stent placement has terminated; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urinary Bladder Overdistension or Overactive Bladder

Drugs mentioned

• Myrbetriq (mirabegron)

Snippet

Sponsor: Southern Illinois University | Conditions: Urinary Bladder, Overactive, Pain | Phase 2 | Status: TERMINATED | Results posted: 2023-06-13